Design of CAR-T Cell Manufacturing Process

Loading...
Thumbnail Image
Penn collection
Senior Design Reports (CBE)
Degree type
Discipline
Subject
Biochemical and Biomolecular Engineering
Chemical Engineering
Engineering
Funder
Grant number
License
Copyright date
Distributor
Related resources
Contributor
Abstract

CAR T-cell therapy is at the frontier of personalized immunotherapy. It is a therapy that essentially reprograms a patient’s own T-cells to attack certain blood cancers. A sample of a patient's T cells are collected from the blood, then modified to produce chimeric antigen receptors (CARs) on their surface. When these CAR T cells are reinfused into the patient, the new receptors enable them to latch onto a specific antigen on the patient's tumor cells and kill them, ideally sending the patient into remission and essentially curing their cancer. Currently, CAR T-cell therapy is FDA approved as standard of care for some forms of aggressive, refractory non-Hodgkin lymphoma and for patients with relapsed or refractory acute lymphoblastic leukemia up to age 25. There is a great deal of development occurring to use this therapy in solid tumor cancers, which will bolster the need for large-scale manufacturing processes. This project seeks to develop and optimize a large-scale parallelizable manufacturing process for CAR-T cell therapy. To begin this manufacturing process, whole blood is drawn from a patient and passed through a filter to collect the leukocytes. These leukocytes are then purified and selected for using antigen markers to isolate purified T-cells. The T-cells are activated and undergo a gene transfer to express the chimeric antigen receptor (CAR) through the immunological reprogramming process. During a week-long expansion phase in parallelized small bioreactor units, the T-cells proliferate until they are comprised primarily of successfully modified T-cells. Due to the personalized nature of CAR-T cell therapy, all doses must be contained in single use reactors and facilities in order to prevent patient cross-contamination. Once T-cells have been harvested, they are processed, formulated and concentrated in a resuspension solution, after which they will be cryopreserved and transported back to the original hospital or clinic for infusion. This process design results a yearly production of 3,000 individual CAR-T doses each year.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2020-04-21
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation
Collection